Breast cancer is the most frequently occurring cancer in women. Chemotherapy in
combination with immunotherapy has been used to treat breast cancer. Atezolizumab …

Estrogen receptor α (ER) is the major driver of∼ 75% of breast cancers, and multiple ER
targeting drugs are routinely used clinically to treat patients with ER+ breast cancer …

Recently, the interplay between autophagy and apoptosis has become an important factor in
chemotherapy for cancer treatment. Inhibition of autophagy may be an effective strategy to …

Breast cancers expressing estrogen receptor α, progesterone receptor, or the human
epidermal growth factor receptor 2 (HER2) proto-oncogene account for approximately 90 …

Breast cancer is the most prevalent type of cancer among women. Several types of drugs,
targeting the specific proteins expressed on the breast cancer cell surface (such as receptor …

Purpose: PARP inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast
and ovarian cancers, but resistance due to reversion of mutated BRCA1/2 and other …

Historically, most drugs target protein orthosteric sites. The gradual emergence of resistance
hampers their therapeutic effectiveness, posing a challenge to drug development …

Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen
receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen …

Androgen receptor (AR) is an attractive target in breast cancer because of its frequent
expression in all the molecular subtypes, especially in estrogen receptor (ER)-positive …

The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …